There is a molecule Americans search for hundreds of thousands of times a month that has not reached a pharmacy shelf. Not because it is banned. Because it has not finished the process.
What it actually is:
“Retatrutide is a triple hormone receptor agonist that targets three pathways: GLP-1, GIP and glucagon receptors.”
“At this time, there is no FDA-approved branded retatrutide product available.”
Where it sits in the family:
“The GLP-1 originally came out as a medication for diabetics. There are receptors in the stomach that make us feel full, and that same signaling helps lower blood sugar, which is how it helps diabetics control their sugar. It also communicates with the brain so your appetite goes down, you feel fuller and more satisfied, and it slows the intestine so your portions naturally get smaller. You eat the same way but smaller portions, and certain foods, like very greasy or very sugary foods, stop appealing to you.”
“Semaglutide was the first one and has just one component, GLP-1. Tirzepatide has two components, GLP-1 and GIP. It helps more with inflammation, helps with more weight loss, and has fewer side effects like nausea, heartburn, and vomiting.”
One receptor. Then two. Retatrutide makes three.
On how I dose the approved ones:
“We start with the smallest dose, which is 2.5 milligrams, for four weeks, and I see how you feel. If you are doing well I increase the dose depending on how you feel. If you are losing a good amount of weight, I keep you at that dose until you stop losing, then we go up again.”
“I give you the four injections for the whole month, and you inject yourself once a week. The injections are like an insulin shot, a tiny drop, usually in the abdomen, alternating sides each week.”
In trial, retatrutide started at 2 mg weekly and stepped up every four weeks.
Why the body fights you in the first place:
“As estrogen starts to drop, the other hormones start to change, the thyroid, insulin, and cortisol, and women tend to start gaining around the middle.”
“Insulin makes you very hungry and tired and causes you to store more fat. The metabolism slows down and cortisol rises, and that is part of why we gain weight.”
“Even if you exercise a lot and eat well, sometimes we need some kind of help.”
On whether the new molecule is the better choice:
“Retatrutide, being a triple agonist targeting GLP-1, GIP, and glucagon receptors, may offer greater weight loss potential than semaglutide and tirzepatide. Semaglutide is a GLP-1 receptor agonist, whereas tirzepatide is a dual GLP-1 and GIP receptor agonist.
“Patient selection should be individualized rather than based on one peptide. Patients with obesity or overweight accompanied by metabolic complications such as prediabetes, insulin resistance, metabolic dysfunction-associated fatty liver, or cardiometabolic risk factors may all be appropriate candidates for any of the GLP forms.”
May. That word is doing real work and I am not going to pretend otherwise. There is no completed head to head trial against tirzepatide.
Why anyone cares this much
Lilly published Phase 3 TRIUMPH-1 in May. At 80 weeks, participants on 12 mg had lost an average of 28.3 percent of their body weight, about 70 pounds. Forty five percent lost at least 30 percent. Two thirds finished with a BMI under 30. A smaller group who ran to 104 weeks averaged 30.3 percent, roughly 85 pounds.
I have spent my career operating on people after weight loss like that. Until recently the only reliable route to those numbers was a surgeon.
The results carried a cost. At the top dose, 42 percent nausea, one in eight reporting abnormal skin sensation, about one in nine quitting over side effects. The lowest dose studied delivered 19 percent weight loss with fewer dropouts than placebo, which tells you the ceiling is not the target for everyone.
Where it stands
Lilly hinted it might file with the FDA before the end of 2026. In July it moved that to the first quarter of 2027, citing manufacturing and quality control data still being assembled. Then the review clock starts.
On sourcing, which is the part that keeps me up:
“An important safety consideration with GLP-1 based therapies and other peptide treatments is the importance of ongoing evaluation, treatment, and follow-up by a qualified licensed medical professional. Patients should undergo appropriate screening before treatment.
“Appropriate clinical oversight and sourcing medication through legitimate, appropriately licensed pharmacies can also help reduce the risk of obtaining counterfeit, contaminated, improperly compounded or otherwise unsafe products from unverified sources.
“Patients should be educated to obtain their medications only through authorized and reputable channels and to avoid products purchased from unverified websites, social media, or any other unauthorized sellers.”
Unverified websites, social media, unauthorized sellers. That is where a great many of those searches end up, and there is no approved product waiting at the other end of any of them. I wrote recently about what the word peptide actually means and why I now ask every surgical patient what they have been injecting. Same problem, newer name.
What I tell people instead
The approved medications work. What I say to patients on them has not changed:
“Your appetite will go down. Many patients stop eating and only eat at mealtime, but I do not want you to do that, because if your blood sugar drops you will feel tired. I want you to eat small amounts during the day, snacking on something like a fruit, so your blood sugar stays more stable. I also want you to eat more protein so you do not lose as much muscle and we burn more fat.”
“Walk twenty to thirty minutes a day. Once you feel a little better, add light weights while you walk. That helps the muscle grow and burns more fat.”
A better obesity medication does appear to be coming. On the optimistic reading it is about a year from a pharmacy. Nothing about that timeline improves by buying a vial from someone who will not tell you where it came from.
For the full trial breakdown, dosing as it was studied, and what to do in the meantime, read the complete guide on the Southwest Plastic Surgery site. The version I wrote for my surgical patients is at agulloplasticsurgery.com, and body contouring after major weight loss is the surgical side of this story.
Call (915) 590-7900, text 1-866-814-0038, or book online at agulloplasticsurgery.com. #StayBeautiful
@RealDrWorldWide on Instagram, TikTok, and Snapchat, @Agullo on X, or @AgulloPlasticSurgery on Facebook.